|
Post by iamwhatiam on Dec 9, 2016 18:38:05 GMT
|
|
|
Post by iamaverb on Dec 10, 2016 20:21:34 GMT
With the new name being surfaced for the Secretary of State, I went back to listen to an old interview Charlie Rose had with Rex Tillerson. In this 1 hour talk Rex talked about the resources Exxon is dedicating to renewable energy, in particular algae, a potential source of biofuel. I found the following research paper from April this year, published in a scientific magazine. As Rex stated, and I agree with, “never bet against science.”
“Marine microalgae are responsible for 40% of global primary production and capture more CO2 than all the rain forests combined1. Diatoms (Bacillariophycea) are the most important group of eukaryotic microalgae, and have enormous ecological significance2,3,4. This group of microalgae can also be used as a source of lipids for biofuels, as well as other applications in bio-, nano- and environmental technology5,6. Studies of microalgae have been hampered by inefficient genome editing methods restricting functional analyses. We developed a highly efficient CRISPR/Cas9 based system optimized for creating stable targeted gene knockouts in the marine diatom P. tricornutum. The two components necessary for this system to function, the Cas9 nuclease and a guide RNA directing the nuclease to a specific DNA sequence, were expressed from the same vector.”
Can you imagine if the CRISPR-Cas9 gene editing were to usher in a new world of energy independence? Trillions. Exciting times lie ahead of us.
|
|
|
Post by iamaverb on Dec 19, 2016 16:00:07 GMT
As the patent battle heats up, the opposing sides are strengthening their positions for the upcoming decision. If anyone has been studying CRISPR-Cas9 then you understand how really big this outcome is going to be. In the short 16 years I have been investing, 3 years full time, I have never seen an opportunity like the one that is developing before us. Here we have perhaps, as many scientist are telling us, the biggest medical breakthrough this century is soon to be awarded the patent rights. Currently there are a thousand labs and researchers working on this 4 year old technology who will have to line up behind one side or the other, or both, depending on the outcome. It appears to me that BIG money is risk adverse and is waiting on the sidelines to see which side emerges victorious in the US Patent battle, so the opportunity is for the SMALL guys like us can join them for the feast at the moment the dinner bell sounds. In my opinion, and in the opinion of some other people far smarter than myself present at the recent hearing, the CRSP & NTLA team will/might receive the patent for the Prokaryotic side of the patents, and EDIT will/might continue with their development of the Eukaryotic based CRISPR-Cas9 system. EDIT circles it's wagons around their patent rightsEditas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies Monday, December 19, 2016 12:00 PM UTC 0 comments -- Company to Receive Global Licenses for Novel CRISPR System Cpf1 and Advanced Forms of Cas9 -- CAMBRIDGE, Mass., Dec. 19, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced it has exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics that will enhance and broaden the range of medicines the Company can develop. These global licensing agreements include intellectual property owned by the Broad Institute of MIT and Harvard (Broad Institute), Harvard University, Massachusetts Institute of Technology (MIT), Wageningen University, the University of Iowa, and the University of Tokyo for the new CRISPR genome editing system known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies. In addition, these licenses employ the inclusive innovation model developed by Broad Institute, Harvard University, and MIT, which is designed to maximize the opportunity for groundbreaking innovations to reach the largest number of patients. ADVERTISING inRead invented by Teads “We are delighted to expand our global CRISPR genome editing leadership and to build on the groundbreaking work of these important academic institutions to develop both the new genome editing system Cpf1 and advanced forms of Cas9,” said Katrine Bosley, President and Chief Executive Officer of Editas Medicine. “With the addition of these significant advancements, we further develop the strongest and most differentiated platform in the fast-moving field of CRISPR, which enables us to design and develop unprecedented genome editing medicines.” CRISPR genome editing has the potential to enable scientists and physicians to create medicines that may be able to treat serious diseases by making precise changes in DNA in the cells of a patient’s body. Cpf1 is a CRISPR genome editing system that has been recently characterized and engineered and which may be applied to make medicines for humans, among other applications. Cpf1 complements the Cas9 genome editing system as the Cpf1 protein is structurally distinct, has independent intellectual property, and has several potential benefits, including: Increasing the number of sites in the genome that can be edited, because it has distinct protospacer adjacent motifs (PAMs); Simpler manufacture and delivery, because the natural system requires only a short, single CRISPR guide RNA and does not include a tracrRNA; and Increased efficiency and accuracy for some forms of gene repair, because it makes staggered DNA cuts. Work of Feng Zhang, Ph.D., and colleagues at the Broad Institute and the McGovern Institute for Brain Research at MIT, with co-authors Eugene Koonin, Ph.D., at the NIH, Aviv Regev, Ph.D., at the Broad Institute and the MIT Department of Biology, and John van der Oost, Ph.D., at Wageningen University, on Cpf1 was published in September 2015. Published data from multiple institutions demonstrate that certain Cpf1 proteins can be harnessed to edit genes with high efficiency and specificity. These licenses also further expand Editas Medicine’s leadership position in Cas9-based genome editing, including advanced forms of Cas9 which can be more specific than the naturally occurring version of Cas9. The licenses announced today also include other aspects of Cas9-based genome editing, specific disease applications, as well as non-exclusive access to a range of supporting research technology. Under the terms of the combined licenses for Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies from the Broad Institute, Harvard University, MIT, Wageningen University, the University of Iowa, and the University of Tokyo, Editas Medicine will make total upfront cash payments of $6.25 million and issue a promissory note totaling $10 million that can be settled in stock or cash over a predefined period. In the future, Editas Medicine may make additional payments, in cash or stock upon reaching goals and targets related to research and development, commercialization, and market capitalization, and will pay royalties on products based on these technologies. The Inclusive Innovation Model These licenses employ the inclusive innovation model, developed by Broad Institute, Harvard University, and MIT, which enables Editas Medicine to devote sufficient investment to develop CRISPR-based genome editing technology to treat human diseases, while enabling broad development of medicines against many diseases. Under this model, Editas Medicine has a right to exclusively use the technology on targets of its choosing for the development of genomic medicines. After an initial period, other companies may apply to license certain CRISPR intellectual property from the institutions for use against genes of interest that are not being pursued by Editas Medicine. The Company then has a pre-defined period to decide whether it intends to pursue the gene of interest and to commit to funding and launch a program. If Editas Medicine is not already working on the gene of interest and chooses not to pursue a new program of its own within this period, then the intellectual property may be made available by the institutions for license to a third party. The inclusive innovation model is aligned with the structure and principles established in the original license from the Broad Institute and Harvard University to Editas Medicine in 2014. In addition, the academic research institutions offer non-exclusive licenses for commercial uses unrelated to human therapeutics, and make CRISPR tools, knowledge, methods, and other intellectual property for genome editing freely available to the academic and non-profit community. And then there is NTLA and CRSP circling their respective wagons and joining forces. Intellia exclusevily license CRISPR technology from DoudnaMARKET NEWS | Fri Dec 16, 2016 | 8:54am EST BRIEF-Crispr Therapeutics, Intellia Therapeutics, Caribou Biosciences and Ers Genomics announce global agreement Dec 16 Crispr Therapeutics Ag - * Crispr Therapeutics, Intellia Therapeutics, Caribou Biosciences and Ers Genomics announce global agreement on the foundational intellectual property for CRISPR/Cas9 gene editing technology * Parties commit to maintain and coordinate prosecution, defense and enforcement of CRISPR/Cas9 foundational patent portfolio worldwide Source text for Eikon: Further company coverage:
|
|
|
Post by iamaverb on Dec 22, 2016 3:56:52 GMT
|
|
|
Post by iamaverb on Dec 23, 2016 16:10:59 GMT
I sent the following email to a Interference Patent attorney with 50 years experience that I chatted with for an hour while standing in line waiting to get into the CRISPR hearing. He was there representing a client that may or may not have a financial interest in this case. Xxxxx,
I am the gentleman (I am using the term loosely) who stood and spoke to you while in line waiting for the CRISPR interference hearing in Alexandria. I enjoyed passing the time and learning about the process from you. I looked for you and your partner afterward to get your opinions of the direction of the presentations and questioning and I drove over to the panel discussion being held at the UW Law School to get a better understanding from people far more informed than me.
If you have any opinions of your own that you are willing to share regarding the hearing would be appreciated. In particular the level and line of questioning the panel judges directed at the two parties, especially the time spent focused on the Doudna attorney. Should I assume anything by the sheer number of exhibits entered by Doudna relative to Zhang?
And Xxxx, would it be possible at the time when you learn of the final decision, that you pass along to me this information and your opinion of the outcome. I am afraid I might miss something in translation. I would be willing to pay you for your help.
Regardless, the day I spent travelling from Texas was considered quality time for me to experience something outside of my normal realm of life.
Sincerely,
Bill Xxxxxxxx I received a lengthy and very informative response to my email from this attorney but because of the following disclosure he included at the end of his email I won't post his response, other than to say he seems to lean towards the Broad and their more lucrative patents. Though I cannot divulge the details of his email response at this time, I will keep the forum informed of the final USPTO Patent decision and his analysis. This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact Oblon by reply email and destroy all copies of the original message. If you are the intended recipient, please be advised that the content of this message is subject to access, review and disclosure by the sender's Email System Administrator. From: Bill Xxxx [mailto:bill@xxxx.com] Sent: Thursday, December 22, 2016 11:25 AM To: Xxxx XxxxSubject: CRISPR-Cas9 Interference Case
|
|
|
Post by iamaverb on Dec 28, 2016 4:32:16 GMT
Dr. Doudna, one of the pioneers of CRISPR and a party to the patent suit, published just today an informative video on the CRISPR-Cas9 system. CRISPR explained
|
|
|
Post by iamaverb on Jan 3, 2017 21:21:09 GMT
Back from vacation in Puerto Escondido, Mx., and back to watching investments. CRSP was up 11% today, EDIT up 5% and NTLA was up 2.4%, all on increased volume. I call this a win. I told my wife this past weekend that I expect these Cas-9 stocks will afford us a beach house on Zicatela Beach, and will make my gains this past year with my O&G stocks look like pocket change. Gotta have goals, right? imo, CRISPR makes a stem cell cure for macular degeneration pale in comparison. The following is an informative article on what to look for in CRISPR-Cas9 this coming year. CRISPR will be a huge story in 2017. Here are 7 things to look for.We’re about to enter a golden age of genetic engineering, where huge advances in gene-editing technology are making it possible for scientists to tweak the DNA of different organisms with incredible, unprecedented precision. Until just a few years ago, altering individual genes in everything from plant cells to mouse cells to human cells was a crude, laborious, and often futile process. Now scientists have developed a technology called CRISPR/Cas9 (or CRISPR for short), which harnesses the immune system of bacteria to snip individual genes, either knocking them out or even inserting new ones in their place. (Here’s our full explainer on CRISPR, which is different from conventional genetic modification techniques.) What’s impressive about CRISPR is how it’s transforming the work of so many scientists in so many different fields. Much of the important work is still in the proof-of-concept stage — for example, proving that you can use CRISPR to control transcription (making an RNA copy of a gene sequence), edit the epigenome, or image the genome in living cells. But as the details get worked out, scientists say they can imagine CRISPR becoming an incredibly powerful tool. “We are getting to a point where we can investigate different combinations of genes, controlling when, where, and how much they are expressed, and investigate the roles of individual bases of DNA,” says Nicola Patron, a molecular and synthetic biologist at the Earlham Institute in the UK. “Understanding what DNA sequences do is what enables us to solve problems in every field of biology from curing human diseases, to growing enough healthy food, to discovering and making new medicines, to understanding why some species are going extinct.” Note that Patron didn’t mention editing genes in human embryos — that is, designing babies with coveted traits like high intelligence or muscular stature. Indeed, most scientists obsessed with CRISPR say this potential use of the technology is much more scientifically challenging and less important than other applications. With 3 billion base pairs, the human genome is so massive that complex modifications will be a major hurdle even with CRISPR. Plus embryo editing is ethically very fraught — it will likely be many years before any scientist in the US gets the green light to try it (though China and other countries will move faster on this front). Designer babies, in other words, are, for now, mainly a sideshow. But we asked Patron and a variety of other scientists what they think are realistically the most exciting ways that scientists might one day change the world using CRISPR. Here are some ideas they put forward. 1) Figure out what different genes actually doIt sounds strange, but even though scientists have sequenced the entire genomes of organisms like mice, corn, and even humans, we still have a lot to learn about what those genes actually do — and which genes are responsible for certain traits or diseases and so on. Piecing this together is an enormously difficult task. CRISPR could, potentially, change that. By knocking out certain genes and then looking at what effects that has, the technology has the potential to help scientists vastly improve their understanding of different genomes. “That’s one of the most exciting uses,” says Jennifer Doudna, one of the early CRISPR pioneers at the University of California Berkeley. “It gives us the potential to uncover what genome sequences are actually telling us about the behavior of different organisms.” The magical revival of the resurrection plant. Wikimedia Commons One fun example: Neal Stewart, a professor of plant sciences at the University of Kentucky, has long been interested in the resurrection plant, which can go into a state of near-death during extreme drought, and then revive when the rain returns. With CRISPR, researchers might be able to puzzle together how this fern actually works — and then possibly see if genetic editing could help other crops harness this skill. 2) Engineer plants to improve food security
Over the next 30 years, we’re going to have to find ways feed another two billion people. That means we’re going to have to grow a lot more food — and fast. One way we might be able to do this is to engineer crops to be more resilient to things like weeds, pests, and drought, and to grow faster. Dan Voytas, a plant geneticist at the University of Minnesota, runs a lab that’s developing methods to use CRISPR for targeted genome modification of plants. Right now, he says he’s working on herbicide-tolerant varieties of cassava for smallholder farmers in Africa. (These plants would be different from conventional GMOs, which are typically created by transplanting genes from other organisms into crops. With CRISPR, you are editing the crop genome directly.) Voytas is also interested in understanding how CRISPR might help improve the photosynthetic efficiency of rice. Plants like rice, potatoes, and cassava — staple foods in much of the developing world — have slower photosynthesis rates in hot environments. If scientists like Voytas can figure out how to get rice to do photosynthesis faster, crop yield could increase dramatically. 3) Identify potential Alzheimer’s treatments
Martin Kampmann is a cell biologist at the Institute for Neurodegenerative Diseases at the University of California San Francisco. Along with his colleagues, he has helped develop a CRISPR-based platform to identify the genes controlling processes that drive neurodegenerative diseases like Alzheimer's and Parkinson's. Kampmann says the goal is to identify new strategies for developing treatments. “It’s a hugely important problem,” he says. “We currently have no therapies that slow the progression of those devastating diseases.” 4) Develop new cancer treatments
Scientists have already been exploring how CRISPR might be used to treat certain types of cancer for a few years. A research team at the University of Pennsylvania recently got approval for a small clinical trial in 2017: They will take out some immune cells from 18 patients and use CRISPR to modify the cells to make them more effective at targeting and destroying cancer cells. They will then transplant these edited cells back into the patients and see if it helps with treatment. But this is only the beginning. For instance, Luke Gilbert of the University of California San Francisco, tells us that he’s excited about using CRISPR to make safer and more effective suppressors for tumors caused by “mistakes” in the DNA. First, though, he and his colleagues need “to evaluate how every gene encoded by the genome dictates cancer cell sensitivity to new anti-cancer drugs” to figure out which ones will work best. 5) Reduce our reliance on petrochemicalsCurrently, the world relies on the hydrocarbon molecules found in fossil fuels to create materials like plastics. But with CRISPR, we could conceivably change that. One team at the University of California Riverside has been exploring how to use CRISPR to manipulate and control a type of yeast that transforms sugars into hydrocarbons. Eventually, the hope is to engineer yeast that can create the necessary building blocks for certain polymers, adhesives, and fragrances — rather than relying on inefficient petroleum-based processes. (Further out, this process could even be used to produce biofuels for vehicles, although much work remains to be done.) And that’s only one project. Other researchers hope CRISPR-engineered yeast can help us reduce our reliance on petrochemicals in a wide variety of areas. “Anything that can be polymerized to make plastic — succinic, fumaric, and malic acids — would be top of my list,” of chemicals to develop, says Sarah Richardson of Ignition Genomics, a private biotech firm in San Francisco. “They could be swapped in to make nylon and polyurethanes that are currently made entirely from benzene made from petrochemicals.” 6) Use plants to make drugs and vaccines
Pharmaceutical makers use all kinds of different systems to produce drugs and vaccines, including bacteria, yeast, and mammal cells. Lately, they’ve been especially keen on turning plants or plant cells into factories for metabolites and proteins. Plants work well because they’re strong, cheap, and have a low risk of contamination with toxins or pathogens. This goes by the name of “molecular pharming.” CRISPR can be helpful here for the targeted insertion of specific genes in plants — and to understand how plants genes are regulated, how they respond to foreign molecules, and how they repair their DNA, says Nicola Patron, a molecular and synthetic biologist at the Earlham Institute UK. Lately, she’s been developing plants that could make human therapies and vaccines that are currently very hard to manufacture. 7) Destroy viruses like HIV, herpes, and hepatitis
While researchers have come a long way in developing treatments for HIV, herpes, hepatitis, and human papilloma virus, or HPV, they still cause disease and still can’t quite be definitively cured. Bryan Richard Cullen at Duke Medical Center says CRISPR can be used to target and destroy these persistent DNA viruses in ways researchers haven’t be able to before. The way he uses CRISPR is to develop a vector, based on different Cas9 proteins encoded by different bacteria, which attack DNA viruses in cultured cells. “We hope to move these studies into animal models in the very near future to see if we can cure animals bearing, for example, an HPV-16 induced tumor, or with a high level [Hepatitis B] infection of their liver,” his website says.
|
|
|
Post by iamaverb on Jan 4, 2017 21:16:02 GMT
There continues to be strength in this segment today. CRSP was up 4.5% today, EDIT up 8.5% and NTLA was up 4%, all on increased volume.
|
|
|
Post by iamaverb on Jan 6, 2017 14:50:55 GMT
Today the USPTO panel of judges denied a request from the Senior Party (UC Berkeley) to introduce additional evidenced into the interference claim. I check the USPTO portal each morning to learn if a final decision has been reached, though I expect news to leak out the day before and share prices to begin to rise and fall in advance of the information going public.
I have asked two interested parties to this suit, one an interference attorney and one a law professor, if they would analyse the outcome and explain it to me in laymen terms when the decision is announced. One wanted me to put them on a $20K retainer and the other will oblige me per gratis. Hmmm...decisions, decisions.
|
|
|
Post by iamaverb on Jan 9, 2017 14:10:10 GMT
EDIT released their agenda today for the upcoming annual J.P. Morgan Healthcare Conference, often called the Superbowl of biotech, which kicks off on January 9, 2017. There will be an expected 10,000 attendees at this conference, a place where companies layout their goals for the next 12 months. Editas released this morning in their PR ". ... this includes achieving the first in vivo proof-of-editing in the retina of non-human primates, as well as the Company’s goal to submit an IND for the LCA10 program by the end of 2017."The link to the EDIT webcast which begins 1:30 central on Wednesday is Editas (EDIT) J.P. Morgan Webcast
EDIT, as well as the other two CRISPR stocks (CRSP & NTLA) are thinly traded which tells me they are not on many of the big boy's radar. This first of the year conference should begin the introduction of CRISPR to the Money. From the press release: Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare ConferenceGLOBENEWSWIRE 7:00 AM ET 9/1/2017 - Company Achieves In Vivo Proof-of-Editing in the Retina of Non-Human Primates - - Unparalleled Genome Editing Platform Includes Cpf1 and Advanced Forms of Cas9 - CAMBRIDGE, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 11, 2017 at 11:30am (PST) at the 35th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc.(EDIT) President and CEO Katrine Bosley will outline the Company’s progress on developing medicines and building the leading genomic medicine company. In her remarks, Ms. Bosley will discuss several components of the Company’s growth, including: Driving Editas Medicine’s unparalleled platform for genome editing medicines. As the only company with access to the CRISPR genome editing systems Cas9, advanced forms of Cas9, and the novel Cpf1 genome editing system, Editas Medicine(EDIT) has the potential to treat the broadest range of diseases through efficient editing of nearly any genetic target. Advancing a pipeline strategy to enable successful product development in the years ahead. For Editas Medicine’s LCA10 program, this includes achieving the first in vivo proof-of-editing in the retina of non-human primates, as well as the Company’s goal to submit an IND for the LCA10 program by the end of 2017. In addition, Ms. Bosley will discuss recent progress in achieving consistent, durable editing in hematopoietic stem cells and high efficiency editing of CAR-T cells. Building the business for the long term by assembling the capabilities to fully develop and commercialize important medicines. This includes aggressively developing valuable partnerships, robust financial resources, an unmatched patent position, and an outstanding team and culture to drive Editas Medicine’s bold vision for years to come. “We had a very strong 2016 that lays the important groundwork to make 2017 a transformative year for Editas Medicine,” said Ms. Bosley. “We are focused on driving our unparalleled platform and executing our pipeline strategy while building the company into the genomic medicine leader. At Editas Medicine(EDIT), we have a bold vision and are excited about unlocking the power of CRISPR to design and develop genome editing therapies for patients suffering from genetically-defined and genetically-treatable diseases.” In addition, Ms. Bosley will outline the Company’s 2017 goals, including driving the following critical initiatives: Submitting an IND for the LCA10 program by year-end 2017; Initiating an LCA10 clinical natural history study in mid-2017; Achieving preclinical proof-of-concept for additional programs; Establishing additional alliances aligned with the Company’s business development strategy; and Continuing to build an outstanding organization and culture. About Editas Medicine(EDIT) Editas Medicine (EDIT) is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
|
|
|
Post by iamaverb on Jan 10, 2017 4:48:15 GMT
The following article is the most comprehensive I have read regarding the patent interference case, the parties that are involved, the corporate structure and tie ups of said parties, licensing agreements, potential upsides and downsides of the patent case, global CRISPR patents and a weighing of the strengths of each party. If you are thinking of placing money on one or more of these companies, this is a MUST READ. A CRISPR Patent Dispute Roadmap
|
|
|
Post by iamaverb on Jan 13, 2017 15:51:06 GMT
Editas Medicine, Inc. (EDIT) PT Set at $35.00 by Jefferies Group
January 11th, 2017 -
Editas Medicine, Inc. (NASDAQ:EDIT) has been given a $35.00 target price by equities researchers at Jefferies Group in a report issued on Wednesday. The firm presently has a “buy” rating on the stock. Jefferies Group’s price target indicates a potential upside of 88.17% from the company’s current price.
Jefferies LLC is an American global investment bank and institutional securities firm headquartered in New York. The firm provides clients with capital markets and financial advisory services, institutional brokerage, securities research, and asset management. This includes mergers and acquisitions, restructuring, and other financial advisory services.
Jefferies was named one of the World's Most Admired Companies by Fortune magazine in 2011, Best Place to Work in the Financial Industry by Here Is The City News in 2010, 2011, 2012 and 2013, and one of the best companies to work for in the UK by The Sunday Times.
Over the past 3 weeks I have shifted my weighted balance between EDIT/CRSP/NTLA from 40%/30%/30% to 80%/10%/10%. EDIT appears to lead the pack with over 400 patent applications pending including the all important Cpf1 patent which greatly improves upon the Cas9 patent which is the center of the dispute.
|
|
cruss
New Member
Posts: 4
|
Post by cruss on Jan 14, 2017 17:07:22 GMT
Thanks for all your posts Iamaverb. Much appreciated.
|
|
|
Post by nateb on Jan 15, 2017 23:29:20 GMT
I started a position in EDIT, the new cpf1 patent did it for me.
|
|
|
Post by iamaverb on Jan 20, 2017 13:44:08 GMT
|
|
|
Post by iamaverb on Jan 23, 2017 1:42:48 GMT
I started a page on fb titled CRISPR-Cas9 Investor in order to expand the potential investor audience for gene editing. This may help to drive more people to The Biotech Investor at the same time. Stop by and LIKE and FOLLOW the page for updates if you breaking news. on Facebook: CRISPR Investor
And speaking of CRISPR, CRSP is currently down 11% on heavy volume. Typically CRSP trades at volumes 1/5 of that of EDIT. At this point CRSP is trading at a volume higher than that of Edit. I sold off all but 500 shares CRSP and NTLA last week based upon my interpretation of the hearing transcripts. I am now 95% weighted with EDIT under my go big or go home strategy.
|
|
|
Post by iamaverb on Jan 23, 2017 21:54:45 GMT
I started a page on fb titled CRISPR-Cas9 Investor in order to expand the potential investor audience for gene editing. This may help to drive more people to The Biotech Investor at the same time. Stop by and LIKE and FOLLOW the page for updates if you breaking news. on Facebook: CRISPR Investor
And speaking of CRISPR, CRSP is currently down 11% on heavy volume. Typically CRSP trades at volumes 1/5 of that of EDIT. At this point CRSP is trading at a volume higher than that of Edit. I sold off all but 500 shares CRSP and NTLA last week based upon my interpretation of the hearing transcripts. I am now 95% weighted with EDIT under my go big or go home strategy. Could this be why CRSP fell today on heavy volume and EDIT's share price rose? As posted earlier on fb. Editas released a 100 plus page 8-K report aftermarket today which details the potentially lucrative: CPF1 LICENSE AGREEMENT by and between THE BROAD INSTITUTE, INC. and EDITAS MEDICINE, INC. December 16, 2016 A lot of sensitive material has been redacted, but the gist of it is Editas has exclusive rights to not only the Broad Institute CRISPR-Cas9 Patents, but also the newer CPF1 Patents which ownership is not in dispute.
|
|
|
Post by tatshensini on Jan 23, 2017 22:03:46 GMT
Thanks imaverb for your posts...a relative in Wisconsin, one of the biggest producers of corn told me about Editas, and how CRISPR it will help him. www.fooddive.com/news/how-crispr-is-changing-the-food-industry/432848/Dan Voytas, a plant geneticist at the University of Minnesota, runs a lab that’s developing methods to use CRISPR for targeted genome modification of plants. Right now, he says he’s working on herbicide-tolerant varieties of cassava for smallholder farmers in Africa. (Traditional GMOs are typically created by transplanting genes from other organisms into crops using a slower, less efficient technique. With CRISPR, you are editing crop genomes with more precision.)
Voytas is also interested in understanding how CRISPR might help improve the photosynthetic efficiency of rice. Plants like rice, potatoes, and cassava — staple foods in much of the developing world — have slower photosynthesis rates in hot environments. If scientists like Voytas can figure out how to get rice to do photosynthesis faster, crop yield could increase dramatically.
|
|
|
Post by iamaverb on Jan 24, 2017 5:16:02 GMT
Thanks imaverb for your posts...a relative in Wisconsin, one of the biggest producers of corn told me about Editas, and how CRISPR it will help him. www.fooddive.com/news/how-crispr-is-changing-the-food-industry/432848/Dan Voytas, a plant geneticist at the University of Minnesota, runs a lab that’s developing methods to use CRISPR for targeted genome modification of plants. Right now, he says he’s working on herbicide-tolerant varieties of cassava for smallholder farmers in Africa. (Traditional GMOs are typically created by transplanting genes from other organisms into crops using a slower, less efficient technique. With CRISPR, you are editing crop genomes with more precision.)
Voytas is also interested in understanding how CRISPR might help improve the photosynthetic efficiency of rice. Plants like rice, potatoes, and cassava — staple foods in much of the developing world — have slower photosynthesis rates in hot environments. If scientists like Voytas can figure out how to get rice to do photosynthesis faster, crop yield could increase dramatically. Absolutely, the CRISPR gene editing tool will remake many things in the world for the betterment of mankind. With so many researchers working on new developments, it may mean it takes the science and benefits out of the hands of just a few big corporations and allows it to develop like a open source code in software. Regardless, the revenue stream should flow through one or more of these three companies in the form of royalties.
|
|
|
Post by tatshensini on Jan 26, 2017 0:18:20 GMT
CRISPR research institute expands into agriculture, microbiology By Robert Sanders, Media relations | JANUARY 24, 2017 An initiative launched two years ago by UC Berkeley and UC San Francisco to use CRISPR-Cas9 gene editing to develop new disease therapies is expanding into research on the planet’s major crops and poorly understood microbiomes, with plans to invest $125 million in these areas over the next five years. IGI will focus on biomedicine, crops and microbiologyThe funds will not only boost support for biomedical research, but also allow the renamed Innovative Genomics Institute to explore the potential of gene editing in the globally important areas of agriculture and microbiology, and fund projects focused on the social and ethical implications of editing human, animal and plant genomes. “The CRISPR-Cas9 technology, which is only four years old, is improving by leaps and bounds and has already altered the way doctors approach disease and scientists do research,” said IGI executive director Jennifer Doudna, a professor of molecular and cell biology and Howard Hughes Medical Institute investigator at UC Berkeley. “The IGI has shown that the technology can cure the defect that causes sickle cell anemia, and we are moving toward clinical trials within a few years.” “But we’ve realized,” she added, “that there are many others arenas in which better gene-editing tools can promote global health, specifically by improving crops and sustaining a healthy microbial environment that has been shown to prevent illness, improve crop yields and nurture a balanced ecosystem. At UC Berkeley we have the expertise in plant science and microbiology research to make a real contribution by designing higher-yield, more pest-resistant crops that a large proportion of the world’s population depend on, and fostering the microbial populations critical to human health and the health of the planet.” linkis.com/news.berkeley.edu/20/7GeUg
|
|